Thursday, June 30, 2022


Evaxion Biotech Expands Its EVX-03 DNA Vaccine Program Into Non-Small Cell Lung Cancer

Latest Posts

NADMED Brings 1st CE-marked NAD+ Analysis Kit to the Market

NADMED technology is based on proprietary extraction and the individual measurement of NAD metabolites, allowing excellent accuracy comparable to mass spectrometry. Q-NAD kits use the same approach for the four NAD metabolites: NAD+, NADH, NADP, and NADPH.

Avacta Announces 2nd Dose Escalation in the Phase I Clinical Study of AVA6000 Pro-doxorubicin

AVA6000 is a novel form of doxorubicin that has been modified with Avacta’s pre|CISION™ FAP-activated delivery platform to improve its safety and therapeutic index. AVA6000 has been designed to limit cell penetration of the drug, and therefore its cell killing effect, until it is specifically activated by fibroblast activation protein a (FAP) which is in high concentration in many solid tumours compared with healthy tissues.

TransCure bioServices Welcomes Cathay Capital to Accelerate its Ambitious Growth

TransCure bioServices has developed an unrivalled quality of services for a large and international customer base, providing c.70 large pharmas and biotech companies with a full spectrum of analytical testing services.

H.E.L Group Releases iso-BTC+ Calorimeter for Isothermal Battery Performance Testing

The iso-BTC+ Calorimeter is designed to characterize thermal behavior and electrical performance of high power battery cells, highlighting regions of increased thermal energy generation and identifying risks of thermal runaway.

Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies, today announced that it has selected EVX-03 as the product candidate within its DNA technology platform to target a new indication with planned regulatory filing in H2 2022.

Evaxion Biotech currently have two product candidates in their DNA technology platform, EVX-02, and EVX-03. Based on very encouraging results from their pre-clinical studies of EVX-03, the company decided to use this candidate in an upcoming clinical trial in a new indication.

Enhanced DNA technology in EVX-03
EVX-03 is optimized with an APC-targeting unit (Antigen-Presenting Cell), which has shown promising pre-clinical data and significant tumor reduction at very low doses as well as a clear dose-response relationship in all our preclinical models.

New Indication
Evaxion has decided to continue the development of EVX-03 in patients with advanced disease and plans to target non-small cell lung cancer (NSCLC) with EVX-03.

“We are very pleased to announce that the data from EVX-03 is very encouraging on all parameters from anti-tumor effect to immunogenicity. That is why we are moving forward with EVX-03, as we firmly believe it will be able to make a difference in multiple indications,” said CEO Lars Staal Wegner.

Dr. Wegner continues: “In the EVX-03 program, we plan to target non-small cell lung cancer as a new indication for this technology because of the vast unmet medical needs, a huge market potential, and the increased potential to demonstrate rapid proof-of-concept in the clinic. We believe that expanding the PIONEER platform into this new cancer indication will significantly broaden the opportunities for our technology.”


According to GlobalData, the total oncology market for NSCLC is currently $23 billion and is projected to be approximately $33 billion by 2029.
Evaxion has a DNA technology platform with two different product candidates:
EVX-02 is currently being tested in a phase 1/2a clinical trial in patients with resectable melanoma. The ongoing clinical trial is expected to be finalized according to plan with a full clinical readout in Q2 2023.
EVX-03 is currently ready for the clinic. Moving forward, Evaxion has chosen EVX-03 as the product candidate for a Phase 1/2a clinical trial in NSCLC due to very encouraging data in the pre-clinical study.
The new strategy to add a different indication to our portfolio has been included in our pipeline – see attachment for details.

Latest Posts

Learn More




Our Sister Publication

Medical Device News Magazine